Evidence map›Paper›PMID 34519433›Full record

ArticleAsia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists2022

Analysis of the trends of polypharmacy and high-dose prescriptions in Japan.

Naotaka Shinfuku

Open access · hybridAbstract read
In one paragraph

Article in Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Analysis of the trends of polypharmacy and high-dose prescriptions in Japan.Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Naotaka ShinfukuGraduate School of Medicine, International Center for Medical Research, Kobe University, Kobe, Japan.ORCID https://orcid.org/0000-0002-7390-9077
Kobe International University · JP

Funding

Chang Gung Memorial Hospital CMRPG83043Institute of Mental Health, Singapore 013/2001Institute of Mental Health, Singapore CRC 249/2008Japan Society for Promotion of Science, JapanTaipei City Government, Taiwan 10501-62-0120Taipei City Government, Taiwan 97001-62-01Taiwan Bureau of National Health Insurance DOH92-NH-1025
6 · The paper itself

Abstract

introductionAfter extensive research, this study explored whether high-dose prescriptions and polypharmacy remain more frequent in Japan than elsewhere. If confirmed, we aimed to identify the factors that contributed to this unique trend.

methodsThe psychotropic drug prescription patterns for patients with schizophrenia in Japan were reviewed. This was based on a large sample collected from surveys of the Research on Asian Psychotropic Prescription Patterns, an international collaborative research project conducted by Asian psychiatrists to monitor prescriptions of psychotropic drugs for people with mental disorders, in 2001, 2004, 2008, and 2016.

resultsThe 2016 Research on Asian Psychotropic Prescription Patterns survey revealed that Japan continued to demonstrate the highest rate of polypharmacy and the highest dosages of psychotropic prescription drugs for patients with schizophrenia among the 15 countries and areas that participated in the survey. DISCUSSION: The Research on Asian Psychotropic Prescription Patterns surveys demonstrated that science plays a limited role in the decision-making process for prescriptions of psychotropic medications. Such prescriptions are influenced by a wide range of factors, such as the national mental health policy, prescription-financing systems, the history of psychiatry in each country, and the prevailing culture. Hospital-based national mental health policies and mental health financing systems have been the primary obstacles to reducing polypharmacy in Japan.

Indexed as

Antipsychotic AgentsSchizophreniaDrug PrescriptionsHumansJapanPolypharmacyPractice Patterns, Physicians'Antipsychotic Agentshigh-dose prescriptionJapanpolypharmacyREAPschizophrenia

Identifiers

PMID34519433
PMCPMC9285042
OpenAlexW3201093977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.